{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:34:08Z","timestamp":1787585648946,"version":"build-2736575974"},"reference-count":208,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":69,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"DOI":"10.1186\/s12951-026-04689-4","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T01:14:31Z","timestamp":1781572471000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Remodeling the pathological airway: advanced nanotechnology for diagnostics and therapeutics in cystic fibrosis"],"prefix":"10.1186","volume":"24","author":[{"given":"Ying","family":"Zou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyi","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoqi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongping","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhonghao","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Gluchman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huazhe","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9490-2062","authenticated-orcid":false,"given":"Chenyu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xudong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"4689_CR1","doi-asserted-by":"publisher","unstructured":"Pallenberg ST, de Lucas EZ, P\u00e1rniczky A, de Bragan\u00e7a RL. Cystic fibrosis year in review 2025. J Cyst Fibros. 2026;0(0). https:\/\/doi.org\/10.1016\/j.jcf.2026.02.010.","DOI":"10.1016\/j.jcf.2026.02.010"},{"issue":"18","key":"4689_CR2","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1056\/NEJMra2216474","volume":"389","author":"H Grasemann","year":"2023","unstructured":"Grasemann H, Ratjen F. Cystic Fibrosis. N Engl J Med. 2023;389(18):1693\u2013707. https:\/\/doi.org\/10.1056\/NEJMra2216474.","journal-title":"N Engl J Med"},{"issue":"176","key":"4689_CR3","doi-asserted-by":"publisher","first-page":"240261","DOI":"10.1183\/16000617.0261-2024","volume":"34","author":"FJ Frost","year":"2025","unstructured":"Frost FJ, Peckham DG, Felton IC, et al. Managing an ageing cystic fibrosis population: challenges and priorities. Eur Respir Rev. 2025;34(176):240261. https:\/\/doi.org\/10.1183\/16000617.0261-2024.","journal-title":"Eur Respir Rev"},{"issue":"2","key":"4689_CR4","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1001\/jama.2021.23280","volume":"327","author":"TM Endres","year":"2022","unstructured":"Endres TM, Konstan MW. What Is Cystic Fibrosis? JAMA. 2022;327(2):191. https:\/\/doi.org\/10.1001\/jama.2021.23280.","journal-title":"JAMA"},{"key":"4689_CR5","doi-asserted-by":"publisher","first-page":"102239","DOI":"10.1016\/j.coph.2022.102239","volume":"65","author":"KA Despotes","year":"2022","unstructured":"Despotes KA, Donaldson SH. Current state of CFTR modulators for treatment of Cystic Fibrosis. Curr Opin Pharmacol. 2022;65:102239. https:\/\/doi.org\/10.1016\/j.coph.2022.102239.","journal-title":"Curr Opin Pharmacol"},{"issue":"8","key":"4689_CR6","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1513\/AnnalsATS.201802-075FR","volume":"15","author":"MT Jennings","year":"2018","unstructured":"Jennings MT, Flume PA. Cystic Fibrosis: Translating Molecular Mechanisms into Effective Therapies. Ann Am Thorac Soc. 2018;15(8):897\u2013902. https:\/\/doi.org\/10.1513\/AnnalsATS.201802-075FR.","journal-title":"Ann Am Thorac Soc"},{"issue":"3","key":"4689_CR7","doi-asserted-by":"publisher","first-page":"118","DOI":"10.5694\/mja2.51837","volume":"218","author":"J Massie","year":"2023","unstructured":"Massie J. Overcoming the burden of cystic fibrosis. Med J Aust. 2023;218(3):118\u20139. https:\/\/doi.org\/10.5694\/mja2.51837.","journal-title":"Med J Aust"},{"issue":"3","key":"4689_CR8","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1097\/MOP.0000000000001458","volume":"37","author":"CE Milla","year":"2025","unstructured":"Milla CE. The globalization of cystic fibrosis care. Curr Opin Pediatr. 2025;37(3):266\u201371. https:\/\/doi.org\/10.1097\/MOP.0000000000001458.","journal-title":"Curr Opin Pediatr"},{"issue":"Supplement2","key":"4689_CR9","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1093\/jpids\/piac052","volume":"11","author":"AC Blanchard","year":"2022","unstructured":"Blanchard AC, Waters VJ. Opportunistic Pathogens in Cystic Fibrosis: Epidemiology and Pathogenesis of Lung Infection. J Pediatr Infect Dis Soc. 2022;11(Supplement2):S3\u201312. https:\/\/doi.org\/10.1093\/jpids\/piac052.","journal-title":"J Pediatr Infect Dis Soc"},{"issue":"1","key":"4689_CR10","doi-asserted-by":"publisher","first-page":"597","DOI":"10.3390\/ijms24010597","volume":"24","author":"V Jean-Pierre","year":"2022","unstructured":"Jean-Pierre V, Boudet A, Sorlin P, et al. Biofilm Formation by Staphylococcus aureus in the Specific Context of Cystic Fibrosis. Int J Mol Sci. 2022;24(1):597. https:\/\/doi.org\/10.3390\/ijms24010597.","journal-title":"Int J Mol Sci"},{"issue":"18","key":"4689_CR11","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1007\/s40265-021-01635-6","volume":"81","author":"D Reynolds","year":"2021","unstructured":"Reynolds D, Kollef M. The Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: An Update. Drugs. 2021;81(18):2117\u201331. https:\/\/doi.org\/10.1007\/s40265-021-01635-6.","journal-title":"Drugs"},{"issue":"4","key":"4689_CR12","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.jcf.2015.03.003","volume":"14","author":"AM Cantin","year":"2015","unstructured":"Cantin AM, Hartl D, Konstan MW, Chmiel JF. Inflammation in cystic fibrosis lung disease: Pathogenesis and therapy. J Cyst Fibros. 2015;14(4):419\u201330. https:\/\/doi.org\/10.1016\/j.jcf.2015.03.003.","journal-title":"J Cyst Fibros"},{"issue":"7\u20138","key":"4689_CR13","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.clinbiochem.2013.12.020","volume":"47","author":"B Dhooghe","year":"2014","unstructured":"Dhooghe B, No\u00ebl S, Huaux F, Leal T. Lung inflammation in cystic fibrosis: pathogenesis and novel therapies. Clin Biochem. 2014;47(7\u20138):539\u201346. https:\/\/doi.org\/10.1016\/j.clinbiochem.2013.12.020.","journal-title":"Clin Biochem"},{"key":"4689_CR14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.prrv.2019.02.003","volume":"31","author":"CW Course","year":"2019","unstructured":"Course CW, Hanks R. Newborn screening for cystic fibrosis: Is there benefit for everyone? Paediatr Respir Rev. 2019;31:3\u20135. https:\/\/doi.org\/10.1016\/j.prrv.2019.02.003.","journal-title":"Paediatr Respir Rev"},{"key":"4689_CR15","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.prrv.2019.02.004","volume":"31","author":"NJ Simmonds","year":"2019","unstructured":"Simmonds NJ. Is it cystic fibrosis? The challenges of diagnosing cystic fibrosis. Paediatr Respir Rev. 2019;31:6\u20138. https:\/\/doi.org\/10.1016\/j.prrv.2019.02.004.","journal-title":"Paediatr Respir Rev"},{"key":"4689_CR16","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/j.jpeds.2016.09.064","volume":"181S","author":"PM Farrell","year":"2017","unstructured":"Farrell PM, White TB, Ren CL, et al. Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation. J Pediatr. 2017;181S:S4\u2013S. 15.e1.","journal-title":"J Pediatr"},{"issue":"2","key":"4689_CR17","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1055\/s-0042-1759881","volume":"44","author":"PJ Barry","year":"2023","unstructured":"Barry PJ, Simmonds NJ. Diagnosing Cystic Fibrosis in Adults. Semin Respir Crit Care Med. 2023;44(2):242\u201351. https:\/\/doi.org\/10.1055\/s-0042-1759881.","journal-title":"Semin Respir Crit Care Med"},{"issue":"1","key":"4689_CR18","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s13052-021-01060-1","volume":"47","author":"C Cimbalo","year":"2021","unstructured":"Cimbalo C, Tosco A, Terlizzi V, et al. Elevated sweat chloride test: is it always cystic fibrosis? Ital J Pediatr. 2021;47(1):112. https:\/\/doi.org\/10.1186\/s13052-021-01060-1.","journal-title":"Ital J Pediatr"},{"issue":"6","key":"4689_CR19","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1373\/clinchem.2017.274670","volume":"64","author":"JR Wiencek","year":"2018","unstructured":"Wiencek JR, Lo SF. Advances in the Diagnosis and Management of Cystic Fibrosis in the Genomic Era. Clin Chem. 2018;64(6):898\u2013908. https:\/\/doi.org\/10.1373\/clinchem.2017.274670.","journal-title":"Clin Chem"},{"issue":"Suppl 1","key":"4689_CR20","doi-asserted-by":"publisher","first-page":"eS25","DOI":"10.1016\/S0929-693X(20)30047-6","volume":"27","author":"A Pagin","year":"2020","unstructured":"Pagin A, Sermet-Gaudelus I, Burgel PR. Genetic diagnosis in practice: From cystic fibrosis to CFTR-related disorders. Arch Pediatr. 2020;27(Suppl 1):eS25\u20139. https:\/\/doi.org\/10.1016\/S0929-693X(20)30047-6.","journal-title":"Arch Pediatr"},{"issue":"10408","key":"4689_CR21","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/S0140-6736(23)01609-4","volume":"402","author":"JL Taylor-Cousar","year":"2023","unstructured":"Taylor-Cousar JL, Robinson PD, Shteinberg M, Downey DG. CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis. Lancet. 2023;402(10408):1171\u201384. https:\/\/doi.org\/10.1016\/S0140-6736(23)01609-4.","journal-title":"Lancet"},{"issue":"173","key":"4689_CR22","doi-asserted-by":"publisher","first-page":"240060","DOI":"10.1183\/16000617.0060-2024","volume":"33","author":"CME Hansen","year":"2024","unstructured":"Hansen CME, Breukelman AJ, van den Bemt PMLA, Zwitserloot AM, van Dijk L, van Boven JFM. Medication adherence to CFTR modulators in patients with cystic fibrosis: a systematic review. Eur Respir Rev. 2024;33(173):240060. https:\/\/doi.org\/10.1183\/16000617.0060-2024.","journal-title":"Eur Respir Rev"},{"issue":"9","key":"4689_CR23","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.ejim.2014.09.018","volume":"25","author":"S Kumar","year":"2014","unstructured":"Kumar S, Tana A, Shankar A. Cystic fibrosis\u2013what are the prospects for a cure? Eur J Intern Med. 2014;25(9):803\u20137. https:\/\/doi.org\/10.1016\/j.ejim.2014.09.018.","journal-title":"Eur J Intern Med"},{"key":"4689_CR24","doi-asserted-by":"publisher","first-page":"113240","DOI":"10.1016\/j.ejmech.2021.113240","volume":"216","author":"T Bandiera","year":"2021","unstructured":"Bandiera T, Galietta LJV. Pharmacological approaches to cystic fibrosis. Eur J Med Chem. 2021;216:113240. https:\/\/doi.org\/10.1016\/j.ejmech.2021.113240.","journal-title":"Eur J Med Chem"},{"key":"4689_CR25","doi-asserted-by":"publisher","first-page":"175346662412978","DOI":"10.1177\/17534666241297877","volume":"18","author":"L Somerville","year":"2024","unstructured":"Somerville L, Borish L, Noth I, Albon D. Modulator-refractory cystic fibrosis: Defining the scope and challenges of an emerging at-risk population. Ther Adv Respir Dis. 2024;18:17534666241297877. https:\/\/doi.org\/10.1177\/17534666241297877.","journal-title":"Ther Adv Respir Dis"},{"issue":"8","key":"4689_CR26","doi-asserted-by":"publisher","first-page":"e71230","DOI":"10.1002\/ppul.71230","volume":"60","author":"GR Oates","year":"2025","unstructured":"Oates GR, Riekert KA, Ford C, et al. Associations Between Socioeconomic Status and Adherence to Medications in People With Cystic Fibrosis. Pediatr Pulmonol. 2025;60(8):e71230. https:\/\/doi.org\/10.1002\/ppul.71230.","journal-title":"Pediatr Pulmonol"},{"issue":"1","key":"4689_CR27","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41467-023-36244-2","volume":"14","author":"L Allen","year":"2023","unstructured":"Allen L, Allen L, Carr SB, et al. Future therapies for cystic fibrosis. Nat Commun. 2023;14(1):693. https:\/\/doi.org\/10.1038\/s41467-023-36244-2.","journal-title":"Nat Commun"},{"key":"4689_CR28","doi-asserted-by":"publisher","first-page":"105267","DOI":"10.1016\/j.phrs.2020.105267","volume":"162","author":"C Fonseca","year":"2020","unstructured":"Fonseca C, Bicker J, Alves G, Falc\u00e3o A, Fortuna A. Cystic fibrosis: Physiopathology and the latest pharmacological treatments. Pharmacol Res. 2020;162:105267. https:\/\/doi.org\/10.1016\/j.phrs.2020.105267.","journal-title":"Pharmacol Res"},{"issue":"3\u20134","key":"4689_CR29","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1080\/17476348.2024.2357210","volume":"18","author":"F Corrao","year":"2024","unstructured":"Corrao F, Kelly-Aubert M, Sermet-Gaudelus I, Semeraro M. Unmet challenges in cystic fibrosis treatment with modulators. Expert Rev Respir Med. 2024;18(3\u20134):145\u201357. https:\/\/doi.org\/10.1080\/17476348.2024.2357210.","journal-title":"Expert Rev Respir Med"},{"key":"4689_CR30","doi-asserted-by":"publisher","first-page":"106876","DOI":"10.1016\/j.mimet.2023.106876","volume":"217\u2013218","author":"S Rano","year":"2024","unstructured":"Rano S, Bhaduri A, Singh M. Nanoparticle-based platforms for targeted drug delivery to the pulmonary system as therapeutics to curb cystic fibrosis: A review. J Microbiol Methods. 2024;217\u2013218:106876. https:\/\/doi.org\/10.1016\/j.mimet.2023.106876.","journal-title":"J Microbiol Methods"},{"issue":"2","key":"4689_CR31","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.jcf.2025.02.012","volume":"24","author":"A Alameeri","year":"2025","unstructured":"Alameeri A, Yavuz BC, Lucca F, Bambir I, Famulska P, Cohen RWF. Cystic fibrosis year in review 2024. J Cyst Fibros. 2025;24(2):218\u201323. https:\/\/doi.org\/10.1016\/j.jcf.2025.02.012.","journal-title":"J Cyst Fibros"},{"issue":"25","key":"4689_CR32","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.2217\/nnm-2021-0427","volume":"17","author":"HB Masanam","year":"2022","unstructured":"Masanam HB, Perumal G, Krishnan S, et al. Advances and opportunities in nanoimaging agents for the diagnosis of inflammatory lung diseases. Nanomed (Lond). 2022;17(25):1981\u20132005. https:\/\/doi.org\/10.2217\/nnm-2021-0427.","journal-title":"Nanomed (Lond)"},{"issue":"10","key":"4689_CR33","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1136\/thoraxjnl-2019-213037","volume":"74","author":"M Doroudian","year":"2019","unstructured":"Doroudian M, MacLoughlin R, Poynton F, Prina-Mello A, Donnelly SC. Nanotechnology based therapeutics for lung disease. Thorax. 2019;74(10):965\u201376. https:\/\/doi.org\/10.1136\/thoraxjnl-2019-213037.","journal-title":"Thorax"},{"issue":"45","key":"4689_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202100692","volume":"17","author":"F Nasrollahi","year":"2021","unstructured":"Nasrollahi F, Haghniaz R, Hosseini V, et al. Micro and nanoscale technologies for diagnosis of viral infections. Small. 2021;17(45):e2100692. https:\/\/doi.org\/10.1002\/smll.202100692.","journal-title":"Small"},{"key":"4689_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119969","volume":"285","author":"N Gulati","year":"2021","unstructured":"Gulati N, Chellappan DK, MacLoughlin R, Dua K, Dureja H. Inhaled nano-based therapeutics for inflammatory lung diseases: recent advances and future prospects. Life Sci. 2021;285:119969. https:\/\/doi.org\/10.1016\/j.lfs.2021.119969.","journal-title":"Life Sci"},{"key":"4689_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114173","volume":"183","author":"V Forest","year":"2022","unstructured":"Forest V, Pourchez J. Nano-delivery to the lung - by inhalation or other routes and why nano when micro is largely sufficient? Adv Drug Deliv Rev. 2022;183:114173. https:\/\/doi.org\/10.1016\/j.addr.2022.114173.","journal-title":"Adv Drug Deliv Rev"},{"issue":"12","key":"4689_CR37","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/s41573-024-01041-z","volume":"23","author":"A Gupta","year":"2024","unstructured":"Gupta A, Rudra A, Reed K, Langer R, Anderson DG. Advanced technologies for the development of infectious disease vaccines. Nat Rev Drug Discov. 2024;23(12):914\u201338. https:\/\/doi.org\/10.1038\/s41573-024-01041-z.","journal-title":"Nat Rev Drug Discov"},{"key":"4689_CR38","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.actbio.2025.07.068","volume":"204","author":"Y Wang","year":"2025","unstructured":"Wang Y, Xuan W, Mao C, Liu Y. Inhalable nucleic acid therapeutics for chronic pulmonary disease: progress, challenges, and prospects. Acta Biomater. 2025;204:187\u2013204. https:\/\/doi.org\/10.1016\/j.actbio.2025.07.068.","journal-title":"Acta Biomater"},{"issue":"18","key":"4689_CR39","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202309748","volume":"11","author":"Q Wang","year":"2024","unstructured":"Wang Q, Bu C, Dai Q, et al. Recent progress in nucleic acid pulmonary delivery toward overcoming physiological barriers and improving transfection efficiency. Adv Sci (Weinh). 2024;11(18):e2309748. https:\/\/doi.org\/10.1002\/advs.202309748.","journal-title":"Adv Sci (Weinh)"},{"issue":"3","key":"4689_CR40","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1091\/mbc.E14-04-0935","volume":"27","author":"G Veit","year":"2016","unstructured":"Veit G, Avramescu RG, Chiang AN, et al. From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations. Mol Biol Cell. 2016;27(3):424\u201333. https:\/\/doi.org\/10.1091\/mbc.E14-04-0935.","journal-title":"Mol Biol Cell"},{"issue":"4","key":"4689_CR41","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1183\/09031936.00228013","volume":"44","author":"MA Mall","year":"2014","unstructured":"Mall MA, Hartl D. CFTR: cystic fibrosis and beyond. Eur Respir J. 2014;44(4):1042\u201354. https:\/\/doi.org\/10.1183\/09031936.00228013.","journal-title":"Eur Respir J"},{"issue":"9","key":"4689_CR42","doi-asserted-by":"publisher","first-page":"a009589","DOI":"10.1101\/cshperspect.a009589","volume":"2","author":"SM Kreda","year":"2012","unstructured":"Kreda SM, Davis CW, Rose MC. CFTR, mucins, and mucus obstruction in cystic fibrosis. Cold Spring Harb Perspect Med. 2012;2(9):a009589. https:\/\/doi.org\/10.1101\/cshperspect.a009589.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"11","key":"4689_CR43","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.3390\/cells10112844","volume":"10","author":"LS Hanssens","year":"2021","unstructured":"Hanssens LS, Duchateau J, Casimir GJ. CFTR Protein: Not Just a Chloride Channel? Cells. 2021;10(11):2844. https:\/\/doi.org\/10.3390\/cells10112844.","journal-title":"Cells"},{"issue":"Suppl 3","key":"4689_CR44","doi-asserted-by":"publisher","first-page":"S84","DOI":"10.1002\/ppul.24530","volume":"54","author":"CB Morrison","year":"2019","unstructured":"Morrison CB, Markovetz MR, Ehre C. Mucus, mucins, and cystic fibrosis. Pediatr Pulmonol. 2019;54(Suppl 3):S84\u201396. https:\/\/doi.org\/10.1002\/ppul.24530.","journal-title":"Pediatr Pulmonol"},{"issue":"6","key":"4689_CR45","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.jcf.2017.06.005","volume":"16","author":"K Kunzelmann","year":"2017","unstructured":"Kunzelmann K, Schreiber R, Hadorn HB. Bicarbonate in cystic fibrosis. J Cyst Fibros. 2017;16(6):653\u201362. https:\/\/doi.org\/10.1016\/j.jcf.2017.06.005.","journal-title":"J Cyst Fibros"},{"issue":"3","key":"4689_CR46","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1136\/thoraxjnl-2015-207588","volume":"71","author":"IJ Haq","year":"2016","unstructured":"Haq IJ, Gray MA, Garnett JP, Ward C, Brodlie M. Airway surface liquid homeostasis in cystic fibrosis: pathophysiology and therapeutic targets. Thorax. 2016;71(3):284\u20137. https:\/\/doi.org\/10.1136\/thoraxjnl-2015-207588.","journal-title":"Thorax"},{"issue":"Suppl 40","key":"4689_CR47","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1002\/ppul.23247","volume":"50","author":"D Borowitz","year":"2015","unstructured":"Borowitz D. CFTR, bicarbonate, and the pathophysiology of cystic fibrosis. Pediatr Pulmonol. 2015;50(Suppl 40):S24\u201330. https:\/\/doi.org\/10.1002\/ppul.23247.","journal-title":"Pediatr Pulmonol"},{"issue":"9636","key":"4689_CR48","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S0140-6736(08)61162-9","volume":"372","author":"PM Quinton","year":"2008","unstructured":"Quinton PM. Cystic fibrosis: impaired bicarbonate secretion and mucoviscidosis. Lancet. 2008;372(9636):415\u20137. https:\/\/doi.org\/10.1016\/S0140-6736(08)61162-9.","journal-title":"Lancet"},{"issue":"6","key":"4689_CR49","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1055\/s-0039-1694021","volume":"40","author":"C Bergeron","year":"2019","unstructured":"Bergeron C, Cantin AM. Cystic Fibrosis: Pathophysiology of Lung Disease. Semin Respir Crit Care Med. 2019;40(6):715\u201326. https:\/\/doi.org\/10.1055\/s-0039-1694021.","journal-title":"Semin Respir Crit Care Med"},{"key":"4689_CR50","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1146\/annurev-pathol-042420-094031","volume":"17","author":"VS Shah","year":"2022","unstructured":"Shah VS, Chivukula RR, Lin B, Waghray A, Rajagopal J. Cystic Fibrosis and the Cells of the Airway Epithelium: What Are Ionocytes and What Do They Do? Annu Rev Pathol. 2022;17:23\u201346. https:\/\/doi.org\/10.1146\/annurev-pathol-042420-094031.","journal-title":"Annu Rev Pathol"},{"key":"4689_CR51","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.nut.2018.03.052","volume":"55\u201356","author":"P Calella","year":"2018","unstructured":"Calella P, Valerio G, Brodlie M, Donini LM, Siervo M. Cystic fibrosis, body composition, and health outcomes: a systematic review. Nutrition. 2018;55\u201356:131\u20139. https:\/\/doi.org\/10.1016\/j.nut.2018.03.052.","journal-title":"Nutrition"},{"key":"4689_CR52","doi-asserted-by":"publisher","first-page":"i859","DOI":"10.1136\/bmj.i859","volume":"352","author":"BS Quon","year":"2016","unstructured":"Quon BS, Rowe SM. New and emerging targeted therapies for cystic fibrosis. BMJ. 2016;352:i859. https:\/\/doi.org\/10.1136\/bmj.i859.","journal-title":"BMJ"},{"issue":"5","key":"4689_CR53","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/s41579-020-00477-5","volume":"19","author":"E Rossi","year":"2021","unstructured":"Rossi E, La Rosa R, Bartell JA, et al. Pseudomonas aeruginosa adaptation and evolution in patients with cystic fibrosis. Nat Rev Microbiol. 2021;19(5):331\u201342. https:\/\/doi.org\/10.1038\/s41579-020-00477-5.","journal-title":"Nat Rev Microbiol"},{"issue":"2","key":"4689_CR54","doi-asserted-by":"publisher","first-page":"233","DOI":"10.4187\/respcare.06697","volume":"65","author":"NL Turcios","year":"2020","unstructured":"Turcios NL. Cystic Fibrosis Lung Disease: An Overview. Respir Care. 2020;65(2):233\u201351. https:\/\/doi.org\/10.4187\/respcare.06697.","journal-title":"Respir Care"},{"key":"4689_CR55","doi-asserted-by":"publisher","first-page":"5677","DOI":"10.2147\/JIR.S365772","volume":"15","author":"AL Montemari","year":"2022","unstructured":"Montemari AL, Manco M, Fiocchi AG, et al. An inflammatory Signature of Glucose Impairment in Cystic Fibrosis. J Inflamm Res. 2022;15:5677\u201385. https:\/\/doi.org\/10.2147\/JIR.S365772.","journal-title":"J Inflamm Res"},{"issue":"2S","key":"4689_CR56","doi-asserted-by":"publisher","first-page":"S40","DOI":"10.1016\/j.jcf.2017.10.004","volume":"17","author":"A Bragonzi","year":"2018","unstructured":"Bragonzi A, Horati H, Kerrigan L, Lor\u00e8 NI, Scholte BJ, Weldon S. Inflammation and host-pathogen interaction: Cause and consequence in cystic fibrosis lung disease. J Cyst Fibros. 2018;17(2S):S40\u20135. https:\/\/doi.org\/10.1016\/j.jcf.2017.10.004.","journal-title":"J Cyst Fibros"},{"issue":"4","key":"4689_CR57","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.3390\/ijms22041952","volume":"22","author":"A Ghigo","year":"2021","unstructured":"Ghigo A, Prono G, Riccardi E, De Rose V. Dysfunctional Inflammation in Cystic Fibrosis Airways: From Mechanisms to Novel Therapeutic Approaches. Int J Mol Sci. 2021;22(4):1952. https:\/\/doi.org\/10.3390\/ijms22041952.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"4689_CR58","doi-asserted-by":"publisher","first-page":"e00138","DOI":"10.1128\/CMR.00138-18","volume":"32","author":"S Malhotra","year":"2019","unstructured":"Malhotra S, Hayes D, Wozniak DJ. Cystic Fibrosis and Pseudomonas aeruginosa: the Host-Microbe Interface. Clin Microbiol Rev. 2019;32(3):e00138\u201318. https:\/\/doi.org\/10.1128\/CMR.00138-18.","journal-title":"Clin Microbiol Rev"},{"issue":"4","key":"4689_CR59","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1152\/physrev.00004.2021","volume":"102","author":"DB Hill","year":"2022","unstructured":"Hill DB, Button B, Rubinstein M, Boucher RC. Physiology and pathophysiology of human airway mucus. Physiol Rev. 2022;102(4):1757\u2013836. https:\/\/doi.org\/10.1152\/physrev.00004.2021.","journal-title":"Physiol Rev"},{"issue":"2","key":"4689_CR60","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1002\/cphy.c090012","volume":"1","author":"IH Young","year":"2011","unstructured":"Young IH, Bye PTP. Gas exchange in disease: asthma, chronic obstructive pulmonary disease, cystic fibrosis, and interstitial lung disease. Compr Physiol. 2011;1(2):663\u201397. https:\/\/doi.org\/10.1002\/cphy.c090012.","journal-title":"Compr Physiol"},{"key":"4689_CR61","doi-asserted-by":"publisher","first-page":"101788","DOI":"10.1016\/j.bpg.2022.101788","volume":"56\u201357","author":"D Ley","year":"2022","unstructured":"Ley D, Turck D. Digestive outcomes in Cystic fibrosis. Best Pract Res Clin Gastroenterol. 2022;56\u201357:101788. https:\/\/doi.org\/10.1016\/j.bpg.2022.101788.","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"6","key":"4689_CR62","doi-asserted-by":"publisher","first-page":"677","DOI":"10.2337\/db22-0949","volume":"72","author":"MS Putman","year":"2023","unstructured":"Putman MS, Norris AW, Hull RL, et al. Cystic Fibrosis-Related Diabetes Workshop: Research Priorities Spanning Disease Pathophysiology, Diagnosis, and Outcomes. Diabetes. 2023;72(6):677\u201389. https:\/\/doi.org\/10.2337\/db22-0949.","journal-title":"Diabetes"},{"key":"4689_CR63","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.urology.2023.06.017","volume":"179","author":"K Campbell","year":"2023","unstructured":"Campbell K, Zarli M, Schuppe K, Wong R, Rahman F, Ramasamy R. Sexual and Reproductive Health Among Men With Cystic Fibrosis. Urology. 2023;179:9\u201315. https:\/\/doi.org\/10.1016\/j.urology.2023.06.017.","journal-title":"Urology"},{"issue":"2","key":"4689_CR64","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/ijns11020024","volume":"11","author":"ME McGarry","year":"2025","unstructured":"McGarry ME, Raraigh KS, Farrell P, et al. Cystic Fibrosis Newborn Screening: A Systematic Review-Driven Consensus Guideline from the United States Cystic Fibrosis Foundation. Int J Neonatal Screen. 2025;11(2):24. https:\/\/doi.org\/10.3390\/ijns11020024.","journal-title":"Int J Neonatal Screen"},{"issue":"12","key":"4689_CR65","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1136\/thoraxjnl-2020-216085","volume":"76","author":"KJ Bayfield","year":"2021","unstructured":"Bayfield KJ, Douglas TA, Rosenow T, et al. Time to get serious about the detection and monitoring of early lung disease in cystic fibrosis. Thorax. 2021;76(12):1255\u201365. https:\/\/doi.org\/10.1136\/thoraxjnl-2020-216085.","journal-title":"Thorax"},{"key":"4689_CR66","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1016\/j.jpeds.2016.09.065","volume":"181S","author":"PM Farrell","year":"2017","unstructured":"Farrell PM, White TB, Howenstine MS, et al. Diagnosis of cystic fibrosis in screened populations. J Pediatr. 2017;181S:S33-S44.e2. https:\/\/doi.org\/10.1016\/j.jpeds.2016.09.065.","journal-title":"J Pediatr"},{"issue":"11","key":"4689_CR67","doi-asserted-by":"publisher","first-page":"5915","DOI":"10.1021\/acssensors.4c01669","volume":"9","author":"R Premadasa","year":"2024","unstructured":"Premadasa R, Wan Z, Almasi P, et al. CFTrack: Advanced Diagnostic, Monitoring, and Tracking Device for Cystic Fibrosis Care. ACS Sens. 2024;9(11):5915\u201325. https:\/\/doi.org\/10.1021\/acssensors.4c01669.","journal-title":"ACS Sens"},{"issue":"2","key":"4689_CR68","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3390\/ijns11020043","volume":"11","author":"N Vardosanidze","year":"2025","unstructured":"Vardosanidze N, Kavlashvili N, Margvelashvili L, et al. Evaluation of Cystic Fibrosis Newborn Screening and Follow-Up Process in Georgia (2022\u20132023). Int J Neonatal Screen. 2025;11(2):43. https:\/\/doi.org\/10.3390\/ijns11020043.","journal-title":"Int J Neonatal Screen"},{"key":"4689_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2025.108374","author":"R L","year":"2025","unstructured":"L R, S K, R S, et al. Molecular diagnosis of respiratory viral infections in cystic fibrosis, sputum versus nasopharyngeal samples. Respiratory medicine. 2025. https:\/\/doi.org\/10.1016\/j.rmed.2025.108374.","journal-title":"Respiratory medicine"},{"issue":"11","key":"4689_CR70","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.3390\/diagnostics12112893","volume":"12","author":"M Auzenbaha","year":"2022","unstructured":"Auzenbaha M, Aleksejeva E, Taurina G, et al. Clinical and Genetic Characterisation of Cystic Fibrosis Patients in Latvia: A Twenty-Five-Year Experience. Diagnostics (Basel). 2022;12(11):2893. https:\/\/doi.org\/10.3390\/diagnostics12112893.","journal-title":"Diagnostics (Basel)"},{"issue":"3","key":"4689_CR71","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.jcf.2021.12.010","volume":"21","author":"A Hatton","year":"2022","unstructured":"Hatton A, Bergougnoux A, Zybert K, et al. Reclassifying inconclusive diagnosis after newborn screening for cystic fibrosis. Moving forward. J Cyst Fibros. 2022;21(3):448\u201355. https:\/\/doi.org\/10.1016\/j.jcf.2021.12.010.","journal-title":"J Cyst Fibros"},{"issue":"2","key":"4689_CR72","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.gene.2014.02.040","volume":"540","author":"LC Bonadia","year":"2014","unstructured":"Bonadia LC, de Lima Marson FA, Ribeiro JD, et al. CFTR genotype and clinical outcomes of adult patients carried as cystic fibrosis disease. Gene. 2014;540(2):183\u201390. https:\/\/doi.org\/10.1016\/j.gene.2014.02.040.","journal-title":"Gene"},{"issue":"4","key":"4689_CR73","doi-asserted-by":"publisher","first-page":"401","DOI":"10.3390\/genes11040401","volume":"11","author":"PM Farrell","year":"2020","unstructured":"Farrell PM, Rock MJ, Baker MW. The Impact of the CFTR Gene Discovery on Cystic Fibrosis Diagnosis, Counseling, and Preventive Therapy. Genes (Basel). 2020;11(4):401. https:\/\/doi.org\/10.3390\/genes11040401.","journal-title":"Genes (Basel)"},{"key":"4689_CR74","doi-asserted-by":"publisher","DOI":"10.3390\/genes11060619","author":"T B","year":"2020","unstructured":"B T, L M, G E. Molecular diagnosis and genetic counseling of cystic fibrosis and related disorders: new challenges. Genes. 2020. https:\/\/doi.org\/10.3390\/genes11060619.","journal-title":"Genes"},{"issue":"6","key":"4689_CR75","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.jcf.2016.10.009","volume":"15","author":"MS Muhlebach","year":"2016","unstructured":"Muhlebach MS, Clancy JP, Heltshe SL, et al. Biomarkers for cystic fibrosis drug development. J Cyst Fibros. 2016;15(6):714\u201323. https:\/\/doi.org\/10.1016\/j.jcf.2016.10.009.","journal-title":"J Cyst Fibros"},{"issue":"6","key":"4689_CR76","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.jcf.2016.10.010","volume":"15","author":"AG Durmowicz","year":"2016","unstructured":"Durmowicz AG. Cystic fibrosis biomarker - Commentary. J Cyst Fibros. 2016;15(6):712\u20133. https:\/\/doi.org\/10.1016\/j.jcf.2016.10.010.","journal-title":"J Cyst Fibros"},{"issue":"4","key":"4689_CR77","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.prrv.2015.05.004","volume":"16","author":"KA Ramsey","year":"2015","unstructured":"Ramsey KA, Schultz A, Stick SM. Biomarkers in paediatric cystic fibrosis lung disease. Paediatr Respir Rev. 2015;16(4):213\u20138. https:\/\/doi.org\/10.1016\/j.prrv.2015.05.004.","journal-title":"Paediatr Respir Rev"},{"issue":"6","key":"4689_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.cppeds.2024.101637","volume":"54","author":"V Terlizzi","year":"2024","unstructured":"Terlizzi V, Farrell PM. Update on advances in cystic fibrosis towards a cure and implications for primary care clinicians. Curr Probl Pediatr Adolesc Health Care. 2024;54(6):101637. https:\/\/doi.org\/10.1016\/j.cppeds.2024.101637.","journal-title":"Curr Probl Pediatr Adolesc Health Care"},{"issue":"587","key":"4689_CR79","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd8109","volume":"13","author":"TR Ray","year":"2021","unstructured":"Ray TR, Ivanovic M, Curtis PM, et al. Soft, skin-interfaced sweat stickers for cystic fibrosis diagnosis and management. Sci Transl Med. 2021;13(587):eabd8109. https:\/\/doi.org\/10.1126\/scitranslmed.abd8109.","journal-title":"Sci Transl Med"},{"issue":"10","key":"4689_CR80","doi-asserted-by":"publisher","first-page":"4163","DOI":"10.1039\/D3MH00340J","volume":"10","author":"JH Ha","year":"2023","unstructured":"Ha JH, Jeong Y, Ahn J, et al. A wearable colorimetric sweat pH sensor-based smart textile for health state diagnosis. Mater Horiz. 2023;10(10):4163\u201371. https:\/\/doi.org\/10.1039\/D3MH00340J.","journal-title":"Mater Horiz"},{"key":"4689_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.jelechem.2024.118569","volume":"971","author":"P Arun Kumar","year":"2024","unstructured":"Arun Kumar P, Pradeep A, Nair BKG, Satheesh Babu TG, Suneesh PV. Highly sensitive disposable test strips for sweat chloride detection using silver nanoparticles decorated reduced graphene oxide. Journal of Electroanalytical Chemistry. 2024;971:118569. https:\/\/doi.org\/10.1016\/j.jelechem.2024.118569.","journal-title":"Journal of Electroanalytical Chemistry"},{"key":"4689_CR82","doi-asserted-by":"publisher","first-page":"116323","DOI":"10.1016\/j.jelechem.2022.116323","volume":"914","author":"J Fan","year":"2022","unstructured":"Fan J, Wang H, Zeng X, Su L, Zhang X. An electrochemical sensor based on ZIF-67\/Ag nanoparticles (NPs)\/polydopamine (PDA) nanocomposites for detecting chloride ion with good reproducibility. J Electroanal Chem. 2022;914:116323. https:\/\/doi.org\/10.1016\/j.jelechem.2022.116323.","journal-title":"J Electroanal Chem"},{"key":"4689_CR83","doi-asserted-by":"publisher","DOI":"10.3389\/fmats.2022.857432","volume":"9","author":"Z Ifrah","year":"2022","unstructured":"Ifrah Z, Shah Rukh A, Muhammad Nauman S, Maryam S, Rahat U. Fluorescence quenching of graphene quantum dots by chloride ions: a potential optical biosensor for cystic fibrosis. Front Mater. 2022;9:857432. https:\/\/doi.org\/10.3389\/fmats.2022.857432.","journal-title":"Front Mater"},{"issue":"9","key":"4689_CR84","doi-asserted-by":"publisher","first-page":"3430","DOI":"10.1109\/JSEN.2013.2257168","volume":"13","author":"EK Wujcik","year":"2013","unstructured":"Wujcik EK, Blasdel NJ, Trowbridge D, Monty CN. Ion sensor for the quantification of sodium in sweat samples. IEEE Sensors J. 2013;13(9):3430\u20136. https:\/\/doi.org\/10.1109\/JSEN.2013.2257168.","journal-title":"IEEE Sensors J"},{"key":"4689_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtice.2024.105919","volume":"168","author":"JC Lim","year":"2025","unstructured":"Lim JC, Gopinath SCB, Tan SM, Chow EMY, Chen Y. Augmented sensitivity in electrolyte determination for sweat analysis: Rapid amperometric quantification by self-induced gold nanorods aggregation. J Taiwan Inst Chem Eng. 2025;168:105919. https:\/\/doi.org\/10.1016\/j.jtice.2024.105919.","journal-title":"J Taiwan Inst Chem Eng"},{"issue":"2","key":"4689_CR86","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.bios.2010.08.043","volume":"26","author":"V Beni","year":"2010","unstructured":"Beni V, Hayes K, Lerga TM, O\u2019Sullivan CK. Development of a gold nano-particle-based fluorescent molecular beacon for detection of cystic fibrosis associated mutation. Biosens Bioelectron. 2010;26(2):307\u201313. https:\/\/doi.org\/10.1016\/j.bios.2010.08.043.","journal-title":"Biosens Bioelectron"},{"issue":"18","key":"4689_CR87","doi-asserted-by":"publisher","first-page":"9842","DOI":"10.1039\/C6NR00926C","volume":"8","author":"AG Mar\u00edn","year":"2016","unstructured":"Mar\u00edn AG, Garc\u00eda-Mendiola T, Bernabeu CN, et al. Gallium plasmonic nanoparticles for label-free DNA and single nucleotide polymorphism sensing. Nanoscale. 2016;8(18):9842\u201351. https:\/\/doi.org\/10.1039\/C6NR00926C.","journal-title":"Nanoscale"},{"issue":"4","key":"4689_CR88","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.bios.2010.06.047","volume":"26","author":"A Bonanni","year":"2010","unstructured":"Bonanni A, Esplandiu MJ, del Valle M. Impedimetric genosensing of DNA polymorphism correlated to cystic fibrosis: A comparison among different protocols and electrode surfaces. Biosens Bioelectron. 2010;26(4):1245\u201351. https:\/\/doi.org\/10.1016\/j.bios.2010.06.047.","journal-title":"Biosens Bioelectron"},{"key":"4689_CR89","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.talanta.2015.01.004","volume":"136","author":"A Bonanni","year":"2015","unstructured":"Bonanni A, Isabel Pividori M, del Valle M. DNA polymorphism sensitive impedimetric detection on gold-nanoislands modified electrodes. Talanta. 2015;136:95\u2013101. https:\/\/doi.org\/10.1016\/j.talanta.2015.01.004.","journal-title":"Talanta"},{"issue":"9","key":"4689_CR90","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1016\/j.bios.2006.08.031","volume":"22","author":"MT Casta\u00f1eda","year":"2007","unstructured":"Casta\u00f1eda MT, Merko\u00e7i A, Pumera M, Alegret S. Electrochemical genosensors for biomedical applications based on gold nanoparticles. Biosens Bioelectron. 2007;22(9):1961\u20137. https:\/\/doi.org\/10.1016\/j.bios.2006.08.031.","journal-title":"Biosens Bioelectron"},{"issue":"4","key":"4689_CR91","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.elecom.2011.01.015","volume":"13","author":"V Beni","year":"2011","unstructured":"Beni V, Gelaw TK, O\u2019Sullivan CK. Study of the combination of the deposition\/stripping of sacrificial metal nano-structures and alkanethiol as a route for genosensor surface preparation. Electrochem Commun. 2011;13(4):325\u20137. https:\/\/doi.org\/10.1016\/j.elecom.2011.01.015.","journal-title":"Electrochem Commun"},{"issue":"10","key":"4689_CR92","doi-asserted-by":"publisher","first-page":"4140","DOI":"10.1109\/TMAG.2005.855340","volume":"41","author":"HA Ferreira","year":"2005","unstructured":"Ferreira HA, Graham DL, Feliciano N, Clarke LA, Amaral MD, Freitas PP. Detection of cystic fibrosis related DNA targets using AC field focusing of magnetic labels and spin-valve sensors. IEEE Trans Magn. 2005;41(10):4140\u20132. https:\/\/doi.org\/10.1109\/TMAG.2005.855340.","journal-title":"IEEE Trans Magn"},{"issue":"9","key":"4689_CR93","doi-asserted-by":"publisher","first-page":"8731","DOI":"10.1021\/acsami.8b14122","volume":"11","author":"R Ivanova","year":"2019","unstructured":"Ivanova R, Benton DCH, Munye MM, Rangseesorranan S, Hart SL, Moss GWJ. A Nanosensor Toolbox for Rapid, Label-Free Measurement of Airway Surface Liquid and Epithelial Cell Function. ACS Appl Mater Interfaces. 2019;11(9):8731\u20139. https:\/\/doi.org\/10.1021\/acsami.8b14122.","journal-title":"ACS Appl Mater Interfaces"},{"key":"4689_CR94","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2024.1363186","author":"M Sveiven","year":"2024","unstructured":"Sveiven M, Serrano AK, Rosenberg J, Conrad DJ, Hall DA, O\u2019Donoghue AJ. A GMR enzymatic assay for quantifying nuclease and peptidase activity. Front Bioeng Biotechnol. 2024. https:\/\/doi.org\/10.3389\/fbioe.2024.1363186.","journal-title":"Front Bioeng Biotechnol"},{"key":"4689_CR95","doi-asserted-by":"publisher","first-page":"135125","DOI":"10.1016\/j.snb.2023.135125","volume":"402","author":"Z Ma","year":"2024","unstructured":"Ma Z, Sun J, Li X, Shan W, Yan Y, Liu Y. Compact fiber sensor for rapid trypsin detection based on the whispering gallery mode with a liquid crystal microdroplet. Sens Actuators B. 2024;402:135125. https:\/\/doi.org\/10.1016\/j.snb.2023.135125.","journal-title":"Sens Actuators B"},{"key":"4689_CR96","doi-asserted-by":"publisher","first-page":"149250","DOI":"10.1016\/j.apsusc.2021.149250","volume":"550","author":"DW Jeong","year":"2021","unstructured":"Jeong DW, Kim KH, Kim BS, Byun YT. Characteristics of highly sensitive and selective nitric oxide gas sensors using defect-functionalized single-walled carbon nanotubes at room temperature. Appl Surf Sci. 2021;550:149250. https:\/\/doi.org\/10.1016\/j.apsusc.2021.149250.","journal-title":"Appl Surf Sci"},{"issue":"20","key":"4689_CR97","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.3390\/cells12202455","volume":"12","author":"VJ Clemente-Su\u00e1rez","year":"2023","unstructured":"Clemente-Su\u00e1rez VJ, Mart\u00edn-Rodr\u00edguez A, Redondo-Fl\u00f3rez L, Villanueva-Tobaldo CV, Y\u00e1\u00f1ez-Sep\u00falveda R, Tornero-Aguilera JF. Epithelial Transport in Disease: An Overview of Pathophysiology and Treatment. Cells. 2023;12(20):2455. https:\/\/doi.org\/10.3390\/cells12202455.","journal-title":"Cells"},{"key":"4689_CR98","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/1476-0711-13-28","volume":"13","author":"D Satana","year":"2014","unstructured":"Satana D, Erkose-Genc G, Tamay Z, Uzun M, Guler N, Erturan Z. Prevalence and drug resistance of mycobacteria in Turkish cystic fibrosis patients. Ann Clin Microbiol Antimicrob. 2014;13:28. https:\/\/doi.org\/10.1186\/1476-0711-13-28.","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"8","key":"4689_CR99","doi-asserted-by":"publisher","first-page":"e43603","DOI":"10.7759\/cureus.43603","volume":"15","author":"H Sreenivasulu","year":"2023","unstructured":"Sreenivasulu H, Muppalla SK, Vuppalapati S, Shokrolahi M, Reddy Pulliahgaru A. Hope in Every Breath: Navigating the Therapeutic Landscape of Cystic Fibrosis. Cureus. 2023;15(8):e43603. https:\/\/doi.org\/10.7759\/cureus.43603.","journal-title":"Cureus"},{"issue":"4","key":"4689_CR100","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.3390\/ijms27042063","volume":"27","author":"RN Singh","year":"2026","unstructured":"Singh RN, Horn MM, Juko M, et al. Restoration of Defective CFTR in Human Nasal Respiratory Epithelial Cells by CFTR Modulators and mRNA Transfection. Int J Mol Sci. 2026;27(4):2063. https:\/\/doi.org\/10.3390\/ijms27042063.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"4689_CR101","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1016\/j.clinthera.2016.08.014","volume":"38","author":"JS Elborn","year":"2016","unstructured":"Elborn JS, Vataire AL, Fukushima A, et al. Comparison of Inhaled Antibiotics for the Treatment of Chronic Pseudomonas aeruginosa Lung Infection in Patients With Cystic Fibrosis: Systematic Literature Review and Network Meta-analysis. Clin Ther. 2016;38(10):2204\u201326. https:\/\/doi.org\/10.1016\/j.clinthera.2016.08.014.","journal-title":"Clin Ther"},{"key":"4689_CR102","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/8901756","volume":"2016","author":"JM Roberts","year":"2016","unstructured":"Roberts JM, Wilcox PG, Quon BS. Evaluating Adult Cystic Fibrosis Care in BC: Disparities in Access to a Multidisciplinary Treatment Centre. Can Respir J. 2016;2016:1\u20137. https:\/\/doi.org\/10.1155\/2016\/8901756.","journal-title":"Can Respir J"},{"key":"4689_CR103","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/8901756","volume":"2016","author":"JM Roberts","year":"2016","unstructured":"Roberts JM, Wilcox PG, Quon BS. Evaluating adult cystic fibrosis care in BC: disparities in access to a multidisciplinary treatment centre. Can Respir J. 2016;2016:1\u20137. https:\/\/doi.org\/10.1155\/2016\/8901756.","journal-title":"Can Respir J"},{"issue":"4","key":"4689_CR104","doi-asserted-by":"publisher","DOI":"10.3390\/genes16040402","volume":"16","author":"GF Parisi","year":"2025","unstructured":"Parisi GF, Terlizzi V, Manti S, et al. Cutting-edge advances in cystic fibrosis: from gene therapy to personalized medicine and holistic management. Genes. 2025;16(4):402. https:\/\/doi.org\/10.3390\/genes16040402.","journal-title":"Genes"},{"key":"4689_CR105","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.coph.2017.09.015","volume":"34","author":"KY Jih","year":"2017","unstructured":"Jih KY, Lin WY, Sohma Y, Hwang TC. CFTR potentiators: from bench to bedside. Curr Opin Pharmacol. 2017;34:98\u2013104. https:\/\/doi.org\/10.1016\/j.coph.2017.09.015.","journal-title":"Curr Opin Pharmacol"},{"issue":"10","key":"4689_CR106","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14102228","volume":"14","author":"T Eason","year":"2022","unstructured":"Eason T, Ramirez G, Clulow AJ, Salim M, Boyd BJ. Revisiting the dissolution of praziquantel in biorelevant media and the impact of digestion of milk on drug dissolution. Pharmaceutics. 2022;14(10):2228. https:\/\/doi.org\/10.3390\/pharmaceutics14102228.","journal-title":"Pharmaceutics"},{"key":"4689_CR107","doi-asserted-by":"publisher","DOI":"10.1177\/17534666241297877","volume":"18","author":"S Lindsay","year":"2024","unstructured":"Lindsay S, Larry B, Imre N, Dana A. Modulator-refractory cystic fibrosis: defining the scope and challenges of an emerging at-risk population. Ther Adv Respir Dis. 2024;18:17534666241297877. https:\/\/doi.org\/10.1177\/17534666241297877.","journal-title":"Ther Adv Respir Dis"},{"issue":"6","key":"4689_CR108","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0179776","volume":"12","author":"VP Narayanaswamy","year":"2017","unstructured":"Narayanaswamy VP, Giatpaiboon S, Baker SM, Wiesmann WP, LiPuma JJ, Townsend SM. Novel glycopolymer sensitizes burkholderia cepacia complex isolates from cystic fibrosis patients to tobramycin and meropenem. PLoS One. 2017;12(6):e0179776. https:\/\/doi.org\/10.1371\/journal.pone.0179776.","journal-title":"PLoS One"},{"issue":"4","key":"4689_CR109","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.00813-22","volume":"10","author":"RA Murphy","year":"2022","unstructured":"Murphy RA, Coates M, Thrane S, et al. Synergistic activity of repurposed peptide drug glatiramer acetate with tobramycin against cystic fibrosis pseudomonas aeruginosa. Microbiology Spectrum. 2022;10(4):e00813-22. https:\/\/doi.org\/10.1128\/spectrum.00813-22.","journal-title":"Microbiology Spectrum"},{"issue":"11","key":"4689_CR110","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1093\/jac\/dks296","volume":"67","author":"Q Yu","year":"2012","unstructured":"Yu Q, Griffin EF, Moreau-Marquis S, Schwartzman JD, Stanton BA, O\u2019Toole GA. In vitro evaluation of tobramycin and aztreonam versus pseudomonas aeruginosa biofilms on cystic fibrosis-derived human airway epithelial cells. J Antimicrob Chemother. 2012;67(11):2673\u201381. https:\/\/doi.org\/10.1093\/jac\/dks296.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"4689_CR111","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jcf.2011.10.003","volume":"11","author":"MW Konstan","year":"2012","unstructured":"Konstan MW, Ratjen F. Effect of dornase alfa on inflammation and lung function: potential role in the early treatment of cystic fibrosis. J Cyst Fibros. 2012;11(2):78\u201383. https:\/\/doi.org\/10.1016\/j.jcf.2011.10.003.","journal-title":"J Cyst Fibros"},{"issue":"3","key":"4689_CR112","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007923.pub6","volume":"2021","author":"R Dentice","year":"2021","unstructured":"Dentice R, Elkins M. Timing of dornase alfa inhalation for cystic fibrosis. Cochrane Database Syst Rev. 2021;2021(3):CD007923. https:\/\/doi.org\/10.1002\/14651858.CD007923.pub6.","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"4689_CR113","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001127.pub5","volume":"2021","author":"C Yang","year":"2021","unstructured":"Yang C, Montgomery M. Dornase alfa for cystic fibrosis. Cochrane Database Syst Rev. 2021;2021(3):CD001127. https:\/\/doi.org\/10.1002\/14651858.CD001127.pub5.","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"4689_CR114","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1164\/rccm.201910-1943SO","volume":"201","author":"MA Mall","year":"2020","unstructured":"Mall MA, Mayer-Hamblett N, Rowe SM. Cystic Fibrosis: Emergence of Highly Effective Targeted Therapeutics and Potential Clinical Implications. Am J Respir Crit Care Med. 2020;201(10):1193\u2013208. https:\/\/doi.org\/10.1164\/rccm.201910-1943SO.","journal-title":"Am J Respir Crit Care Med"},{"key":"4689_CR115","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.jconrel.2020.07.011","volume":"326","author":"AM Shen","year":"2020","unstructured":"Shen AM, Minko T. Pharmacokinetics of inhaled nanotherapeutics for pulmonary delivery. J Control Release. 2020;326:222\u201344. https:\/\/doi.org\/10.1016\/j.jconrel.2020.07.011.","journal-title":"J Control Release"},{"issue":"4","key":"4689_CR116","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-023-02559-y","volume":"24","author":"HW Chan","year":"2023","unstructured":"Chan HW, Chow S, Zhang X, Zhao Y, Tong HHY, Chow SF. Inhalable nanoparticle-based dry powder formulations for respiratory diseases: challenges and strategies for translational research. AAPS PharmSciTech. 2023;24(4):98. https:\/\/doi.org\/10.1208\/s12249-023-02559-y.","journal-title":"AAPS PharmSciTech"},{"issue":"1","key":"4689_CR117","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15010162","volume":"15","author":"ME Ritivoiu","year":"2023","unstructured":"Ritivoiu ME, Dr\u0103goi CM, Matei D, et al. Current and Future Therapeutic Approaches of Exocrine Pancreatic Insufficiency in Children with Cystic Fibrosis in the Era of Personalized Medicine. Pharmaceutics. 2023;15(1):162. https:\/\/doi.org\/10.3390\/pharmaceutics15010162.","journal-title":"Pharmaceutics"},{"issue":"4","key":"4689_CR118","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.jpha.2021.10.003","volume":"12","author":"H Cheng","year":"2022","unstructured":"Cheng H, Liu J, Tan Y, Feng W, Peng C. Interactions between gut microbiota and berberine, a necessary procedure to understand the mechanisms of berberine. J Pharm Anal. 2022;12(4):541\u201355. https:\/\/doi.org\/10.1016\/j.jpha.2021.10.003.","journal-title":"J Pharm Anal"},{"issue":"6","key":"4689_CR119","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3390\/pharmaceutics11060286","volume":"11","author":"NR Shah","year":"2019","unstructured":"Shah NR, Bulitta JB, Kinzig M, et al. Novel Population Pharmacokinetic Approach to Explain the Differences between Cystic Fibrosis Patients and Healthy Volunteers via Protein Binding. Pharmaceutics. 2019;11(6):286. https:\/\/doi.org\/10.3390\/pharmaceutics11060286.","journal-title":"Pharmaceutics"},{"issue":"1","key":"4689_CR120","doi-asserted-by":"publisher","DOI":"10.1080\/10717544.2025.2544683","volume":"32","author":"Y Gao","year":"2025","unstructured":"Gao Y, Wang W, Yue X, et al. Inhalable nanoparticle-based delivery systems for the treatment of pulmonary infections: status quo and barrier-overcoming strategies. Drug Delivery. 2025;32(1):2544683. https:\/\/doi.org\/10.1080\/10717544.2025.2544683.","journal-title":"Drug Delivery"},{"key":"4689_CR121","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s12951-022-01307-x","volume":"20","author":"S He","year":"2022","unstructured":"He S, Gui J, Xiong K, Chen M, Gao H, Fu Y. A roadmap to pulmonary delivery strategies for the treatment of infectious lung diseases. J Nanobiotechnol. 2022;20:101. https:\/\/doi.org\/10.1186\/s12951-022-01307-x.","journal-title":"J Nanobiotechnol"},{"issue":"13","key":"4689_CR122","doi-asserted-by":"publisher","first-page":"7098","DOI":"10.3390\/ijms25137098","volume":"25","author":"ME Hansen","year":"2024","unstructured":"Hansen ME, Ibrahim Y, Desai TA, Koval M. Nanostructure-mediated transport of therapeutics through epithelial barriers. Int J Mol Sci. 2024;25(13):7098. https:\/\/doi.org\/10.3390\/ijms25137098.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"4689_CR123","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1080\/17425247.2023.2282535","volume":"20","author":"G Kwak","year":"2023","unstructured":"Kwak G, Lee D, Suk JS. Advanced approaches to overcome biological barriers in respiratory and systemic routes of administration for enhanced nucleic acid delivery to the lung. Expert Opin Drug Delivery. 2023;20(11):1531\u201352. https:\/\/doi.org\/10.1080\/17425247.2023.2282535.","journal-title":"Expert Opin Drug Delivery"},{"key":"4689_CR124","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.addr.2020.06.007","volume":"167","author":"JA Finbloom","year":"2020","unstructured":"Finbloom JA, Sousa F, Stevens MM, Desai TA. Engineering the drug carrier biointerface to overcome biological barriers to drug delivery. Adv Drug Delivery Rev. 2020;167:89\u2013108. https:\/\/doi.org\/10.1016\/j.addr.2020.06.007.","journal-title":"Adv Drug Delivery Rev"},{"key":"4689_CR125","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/s12951-023-01971-7","volume":"21","author":"Q Wan","year":"2023","unstructured":"Wan Q, Zhang X, Zhou D, et al. Inhaled nano-based therapeutics for pulmonary fibrosis: recent advances and future prospects. J Nanobiotechnol. 2023;21:215. https:\/\/doi.org\/10.1186\/s12951-023-01971-7.","journal-title":"J Nanobiotechnol"},{"issue":"9","key":"4689_CR126","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.3390\/pharmaceutics14091974","volume":"14","author":"YB Zhang","year":"2022","unstructured":"Zhang YB, Xu D, Bai L, Zhou YM, Zhang H, Cui YL. A review of non-invasive drug delivery through respiratory routes. Pharmaceutics. 2022;14(9):1974. https:\/\/doi.org\/10.3390\/pharmaceutics14091974.","journal-title":"Pharmaceutics"},{"issue":"5","key":"4689_CR127","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1080\/17425247.2021.1854222","volume":"18","author":"D Chen","year":"2021","unstructured":"Chen D, Liu J, Wu J, Suk JS. Enhancing nanoparticle penetration through airway mucus to improve drug delivery efficacy in the lung. Expert Opin Drug Delivery. 2021;18(5):595\u2013606. https:\/\/doi.org\/10.1080\/17425247.2021.1854222.","journal-title":"Expert Opin Drug Delivery"},{"issue":"7","key":"4689_CR128","doi-asserted-by":"publisher","first-page":"3542","DOI":"10.1021\/acs.molpharmaceut.5c00118","volume":"22","author":"MP Costa","year":"2025","unstructured":"Costa MP, Abdu JOC, de Moura MFCS, et al. Exploring the potential of PLGA nanoparticles for enhancing pulmonary drug delivery. Mol Pharmaceutics. 2025;22(7):3542\u201362. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.5c00118.","journal-title":"Mol Pharmaceutics"},{"key":"4689_CR129","doi-asserted-by":"publisher","first-page":"12485","DOI":"10.2147\/IJN.S538382","volume":"20","author":"X Zhang","year":"2025","unstructured":"Zhang X, Tu S, Tian J, et al. Liposome-based nanoparticle delivery systems for lung diseases: opportunities and challenges. Int J Nanomed. 2025;20:12485\u2013509. https:\/\/doi.org\/10.2147\/IJN.S538382.","journal-title":"Int J Nanomed"},{"issue":"3","key":"4689_CR130","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1165\/rcmb.2020-0306TR","volume":"64","author":"Z Deng","year":"2021","unstructured":"Deng Z, Kalin GT, Shi D, Kalinichenko VV. Nanoparticle delivery systems with cell-specific targeting for pulmonary diseases. Am J Respir Cell Mol Biol. 2021;64(3):292\u2013307. https:\/\/doi.org\/10.1165\/rcmb.2020-0306TR.","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"3","key":"4689_CR131","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.3390\/ijms25031933","volume":"25","author":"M Abrami","year":"2024","unstructured":"Abrami M, Biasin A, Tescione F, et al. Mucus structure, viscoelastic properties, and composition in chronic respiratory diseases. Int J Mol Sci. 2024;25(3):1933. https:\/\/doi.org\/10.3390\/ijms25031933.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"4689_CR132","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1152\/physrev.00004.2021","volume":"102","author":"DB Hill","year":"2022","unstructured":"Hill DB, Button B, Rubinstein M, Boucher RC. Physiology and pathophysiology of human airway mucus. Physiol Rev. 2022;102(4):1757\u2013836. https:\/\/doi.org\/10.1152\/physrev.00004.2021.","journal-title":"Physiol Rev"},{"issue":"10","key":"4689_CR133","doi-asserted-by":"publisher","first-page":"6558","DOI":"10.1021\/acsbiomaterials.4c01271","volume":"10","author":"CL O\u2019Brien","year":"2024","unstructured":"O\u2019Brien CL, Spencer S, Jafari N, et al. Modeling cystic fibrosis chronic infection using engineered mucus-like hydrogels. ACS Biomater Sci Eng. 2024;10(10):6558\u201368. https:\/\/doi.org\/10.1021\/acsbiomaterials.4c01271.","journal-title":"ACS Biomater Sci Eng"},{"key":"4689_CR134","doi-asserted-by":"publisher","first-page":"122661","DOI":"10.1016\/j.ijpharm.2023.122661","volume":"634","author":"R Pangeni","year":"2023","unstructured":"Pangeni R, Meng T, Poudel S, et al. Airway mucus in pulmonary diseases: muco-adhesive and muco-penetrating particles to overcome the airway mucus barriers. Int J Pharm. 2023;634:122661. https:\/\/doi.org\/10.1016\/j.ijpharm.2023.122661.","journal-title":"Int J Pharm"},{"issue":"3","key":"4689_CR135","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s00441-016-2562-z","volume":"367","author":"Z Zhou-Suckow","year":"2017","unstructured":"Zhou-Suckow Z, Duerr J, Hagner M, Agrawal R, Mall MA. Airway mucus, inflammation and remodeling: emerging links in the pathogenesis of chronic lung diseases. Cell Tissue Res. 2017;367(3):537\u201350. https:\/\/doi.org\/10.1007\/s00441-016-2562-z.","journal-title":"Cell Tissue Res"},{"key":"4689_CR136","doi-asserted-by":"publisher","first-page":"127152","DOI":"10.1016\/j.micres.2022.127152","volume":"263","author":"F Bugli","year":"2022","unstructured":"Bugli F, Martini C, Di Vito M, et al. Antimicrobial peptides for tackling cystic fibrosis related bacterial infections: a review. Microbiol Res. 2022;263:127152. https:\/\/doi.org\/10.1016\/j.micres.2022.127152.","journal-title":"Microbiol Res"},{"issue":"13","key":"4689_CR137","doi-asserted-by":"publisher","first-page":"9050","DOI":"10.1021\/acs.jmedchem.2c00270","volume":"65","author":"D Ben Hur","year":"2022","unstructured":"Ben Hur D, Kapach G, Wani NA, et al. Antimicrobial peptides against multidrug-resistant pseudomonas aeruginosa biofilm from cystic fibrosis patients. J Med Chem. 2022;65(13):9050\u201362. https:\/\/doi.org\/10.1021\/acs.jmedchem.2c00270.","journal-title":"J Med Chem"},{"issue":"10","key":"4689_CR138","doi-asserted-by":"publisher","first-page":"CD009528","DOI":"10.1002\/14651858.CD009528.pub4","volume":"10","author":"V Waters","year":"2017","unstructured":"Waters V, Ratjen F. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis. Cochrane Database Syst Rev. 2017;10(10):CD009528. https:\/\/doi.org\/10.1002\/14651858.CD009528.pub4.","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"4689_CR139","doi-asserted-by":"publisher","first-page":"CD006961","DOI":"10.1002\/14651858.CD006961.pub5","volume":"5","author":"S Smith","year":"2020","unstructured":"Smith S, Ratjen F, Remmington T, Waters V. Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of pseudomonas aeruginosa in cystic fibrosis. Cochrane Database Syst Rev. 2020;5(5):CD006961. https:\/\/doi.org\/10.1002\/14651858.CD006961.pub5.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"4689_CR140","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1055\/s-0042-1760250","volume":"44","author":"T Milinic","year":"2023","unstructured":"Milinic T, McElvaney OJ, Goss CH. Diagnosis and management of cystic fibrosis exacerbations. Semin Respir Crit Care Med. 2023;44(2):225\u201341. https:\/\/doi.org\/10.1055\/s-0042-1760250.","journal-title":"Semin Respir Crit Care Med"},{"issue":"1","key":"4689_CR141","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s12931-024-02794-2","volume":"25","author":"GC Zhou","year":"2024","unstructured":"Zhou GC, Wang Z, Palipana AK, et al. Predicting lung function decline in cystic fibrosis: the impact of initiating ivacaftor therapy. Respir Res. 2024;25(1):187. https:\/\/doi.org\/10.1186\/s12931-024-02794-2.","journal-title":"Respir Res"},{"issue":"3","key":"4689_CR142","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1080\/1040841X.2023.2186215","volume":"50","author":"C Chen","year":"2024","unstructured":"Chen C, Shi J, Wang D, Kong P, Wang Z, Liu Y. Antimicrobial peptides as promising antibiotic adjuvants to combat drug-resistant pathogens. Crit Rev Microbiol. 2024;50(3):267\u201384. https:\/\/doi.org\/10.1080\/1040841X.2023.2186215.","journal-title":"Crit Rev Microbiol"},{"issue":"10","key":"4689_CR143","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s00203-024-04133-x","volume":"206","author":"M Girdhar","year":"2024","unstructured":"Girdhar M, Sen A, Nigam A, Oswalia J, Kumar S, Gupta R. Antimicrobial peptide-based strategies to overcome antimicrobial resistance. Arch Microbiol. 2024;206(10):411. https:\/\/doi.org\/10.1007\/s00203-024-04133-x.","journal-title":"Arch Microbiol"},{"issue":"14","key":"4689_CR144","doi-asserted-by":"publisher","first-page":"11680","DOI":"10.3390\/ijms241411680","volume":"24","author":"P Li","year":"2023","unstructured":"Li P, Yin R, Cheng J, Lin J. Bacterial biofilm formation on biomaterials and approaches to its treatment and prevention. Int J Mol Sci. 2023;24(14):11680. https:\/\/doi.org\/10.3390\/ijms241411680.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"4689_CR145","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1080\/17425247.2021.1874343","volume":"18","author":"DL Gbian","year":"2021","unstructured":"Gbian DL, Omri A. Current and novel therapeutic strategies for the management of cystic fibrosis. Expert Opin Drug Deliv. 2021;18(5):535\u201352. https:\/\/doi.org\/10.1080\/17425247.2021.1874343.","journal-title":"Expert Opin Drug Deliv"},{"issue":"1","key":"4689_CR146","doi-asserted-by":"publisher","DOI":"10.1186\/s12866-023-02832-x","volume":"23","author":"DRA Sanya","year":"2023","unstructured":"Sanya DRA, On\u00e9sime D, Vizzarro G, Jacquier N. Recent advances in therapeutic targets identification and development of treatment strategies towards pseudomonas aeruginosa infections. BMC Microbiol. 2023;23(1):86. https:\/\/doi.org\/10.1186\/s12866-023-02832-x.","journal-title":"BMC Microbiol"},{"issue":"10408","key":"4689_CR147","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/S0140-6736(23)01609-4","volume":"402","author":"JL Taylor-Cousar","year":"2023","unstructured":"Taylor-Cousar JL, Robinson PD, Shteinberg M, Downey DG. CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis. Lancet. 2023;402(10408):1171\u201384. https:\/\/doi.org\/10.1016\/S0140-6736(23)01609-4.","journal-title":"Lancet"},{"issue":"14","key":"4689_CR148","doi-asserted-by":"publisher","first-page":"3712","DOI":"10.1016\/j.cell.2024.04.046","volume":"187","author":"F Liu","year":"2024","unstructured":"Liu F, Kaplan AL, Levring J, et al. Structure-based discovery of CFTR potentiators and inhibitors. Cell. 2024;187(14):3712-3725.e34. https:\/\/doi.org\/10.1016\/j.cell.2024.04.046.","journal-title":"Cell"},{"issue":"5","key":"4689_CR149","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101544","volume":"5","author":"M Bulcaen","year":"2024","unstructured":"Bulcaen M, Kortleven P, Liu RB, et al. Prime editing functionally corrects cystic fibrosis-causing CFTR mutations in human organoids and airway epithelial cells. Cell Rep Med. 2024;5(5):101544. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101544.","journal-title":"Cell Rep Med"},{"issue":"4","key":"4689_CR150","doi-asserted-by":"publisher","first-page":"263","DOI":"10.3390\/arm92040026","volume":"92","author":"S Anwar","year":"2024","unstructured":"Anwar S, Peng JL, Zahid KR, Zhou YM, Ali Q, Qiu CR. Cystic fibrosis: understanding cystic fibrosis transmembrane regulator mutation classification and modulator therapies. Adv Respir Med. 2024;92(4):263\u201377. https:\/\/doi.org\/10.3390\/arm92040026.","journal-title":"Adv Respir Med"},{"issue":"2","key":"4689_CR151","doi-asserted-by":"publisher","first-page":"2202153","DOI":"10.1183\/13993003.02153-2022","volume":"62","author":"L Schaupp","year":"2023","unstructured":"Schaupp L, Addante A, V\u00f6ller M, et al. Longitudinal effects of elexacaftor\/tezacaftor\/ivacaftor on sputum viscoelastic properties, airway infection and inflammation in patients with cystic fibrosis. Eur Respir J. 2023;62(2):2202153. https:\/\/doi.org\/10.1183\/13993003.02153-2022.","journal-title":"Eur Respir J"},{"issue":"3","key":"4689_CR152","doi-asserted-by":"publisher","DOI":"10.1007\/s12247-026-10505-1","volume":"21","author":"H Patel","year":"2026","unstructured":"Patel H, Kandukuri S, Patel M, Tamboli A. Formulation and Evaluation of Surface Engineered CFTR Modulator Nanoparticles for the Treatment of Cystic Fibrosis. J Pharm Innov. 2026;21(3):267. https:\/\/doi.org\/10.1007\/s12247-026-10505-1.","journal-title":"J Pharm Innov"},{"issue":"1","key":"4689_CR153","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.cell.2021.12.009","volume":"185","author":"K Fiedorczuk","year":"2022","unstructured":"Fiedorczuk K, Chen J. Mechanism of CFTR correction by type I folding correctors. Cell. 2022;185(1):158-168.e11. https:\/\/doi.org\/10.1016\/j.cell.2021.12.009.","journal-title":"Cell"},{"key":"4689_CR154","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2025.11.008","author":"S Castanier","year":"2026","unstructured":"Castanier S, Elbahnsi A, Chevalier B, et al. CFTR correctors potentiate gating mutants causing cystic fibrosis. Journal of Cystic Fibrosis. 2026. https:\/\/doi.org\/10.1016\/j.jcf.2025.11.008.","journal-title":"Journal of Cystic Fibrosis"},{"issue":"2","key":"4689_CR155","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1055\/s-0042-1758851","volume":"44","author":"L Regard","year":"2023","unstructured":"Regard L, Martin C, Da Silva J, Burgel PR. CFTR modulators: current status and evolving knowledge. Semin Respir Crit Care Med. 2023;44(2):186\u201395. https:\/\/doi.org\/10.1055\/s-0042-1758851.","journal-title":"Semin Respir Crit Care Med"},{"key":"4689_CR156","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.jconrel.2019.01.025","volume":"296","author":"OB Garbuzenko","year":"2019","unstructured":"Garbuzenko OB, Kbah N, Kuzmov A, Pogrebnyak N, Pozharov V, Minko T. Inhalation treatment of cystic fibrosis with lumacaftor and ivacaftor co-delivered by nanostructured lipid carriers. Journal of Controlled Release. 2019;296:225\u201331. https:\/\/doi.org\/10.1016\/j.jconrel.2019.01.025.","journal-title":"Journal of Controlled Release"},{"issue":"7","key":"4689_CR157","doi-asserted-by":"publisher","DOI":"10.3390\/cells11071243","volume":"11","author":"F Saluzzo","year":"2022","unstructured":"Saluzzo F, Riberi L, Messore B, et al. CFTR modulator therapies: potential impact on airway infections in cystic fibrosis. Cells. 2022;11(7):1243. https:\/\/doi.org\/10.3390\/cells11071243.","journal-title":"Cells"},{"issue":"9","key":"4689_CR158","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/s41573-024-00977-6","volume":"23","author":"PR Cullis","year":"2024","unstructured":"Cullis PR, Felgner PL. The 60-year evolution of lipid nanoparticles for nucleic acid delivery. Nat Rev Drug Discov. 2024;23(9):709\u201322. https:\/\/doi.org\/10.1038\/s41573-024-00977-6.","journal-title":"Nat Rev Drug Discov"},{"key":"4689_CR159","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2025.107622","volume":"114","author":"H Ho\u0159avov\u00e1","year":"2025","unstructured":"Ho\u0159avov\u00e1 H, Pe\u0161t\u00e1lov\u00e1 A, Pavlokov\u00e1 S, K\u00e1nsk\u00e1 J, L\u00edzal F, Gajdziok J. Spray-dried solid inhalable N-acetylcysteine microparticles: preparation and mucolytic activity testing. Journal of Drug Delivery Science and Technology. 2025;114:107622. https:\/\/doi.org\/10.1016\/j.jddst.2025.107622.","journal-title":"Journal of Drug Delivery Science and Technology"},{"key":"4689_CR160","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2026.107463","volume":"220","author":"AB Cotter","year":"2026","unstructured":"Cotter AB, Costa C, Alhajj N, et al. Inhalable dry powder formulations of the commercialised form of deoxyribonuclease I - a dried alternative for the treatment of cystic fibrosis. European Journal of Pharmaceutical Sciences. 2026;220:107463. https:\/\/doi.org\/10.1016\/j.ejps.2026.107463.","journal-title":"European Journal of Pharmaceutical Sciences"},{"issue":"5","key":"4689_CR161","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002011.pub3","volume":"5","author":"E Main","year":"2023","unstructured":"Main E, Rand S. Conventional chest physiotherapy compared to other airway clearance techniques for cystic fibrosis. Cochrane Database Syst Rev. 2023;5(5):CD002011. https:\/\/doi.org\/10.1002\/14651858.CD002011.pub3.","journal-title":"Cochrane Database Syst Rev"},{"issue":"Pt 1","key":"4689_CR162","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2026.150145","volume":"340","author":"A Grigoletto","year":"2026","unstructured":"Grigoletto A, Mori G, Delfino D, et al. Therapeutic potential of a long-acting form of rhDNase I for the treatment of cystic fibrosis. Int J Biol Macromol. 2026;340(Pt 1):150145. https:\/\/doi.org\/10.1016\/j.ijbiomac.2026.150145.","journal-title":"Int J Biol Macromol"},{"key":"4689_CR163","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.2147\/COPD.S474512","volume":"19","author":"P Rogliani","year":"2024","unstructured":"Rogliani P, Manzetti GM, Gholamalishahi S, Cazzola M, Calzetta L. Impact of N-acetylcysteine on mucus hypersecretion in the airways: a systematic review. International Journal of Chronic Obstructive Pulmonary Disease. 2024;19:2347\u201360. https:\/\/doi.org\/10.2147\/COPD.S474512.","journal-title":"International Journal of Chronic Obstructive Pulmonary Disease"},{"key":"4689_CR164","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2026.107463","volume":"220","author":"AB Cotter","year":"2026","unstructured":"Cotter AB, Costa C, Alhajj N, et al. Inhalable dry powder formulations of the commercialised form of deoxyribonuclease I - a dried alternative for the treatment of cystic fibrosis. European Journal of Pharmaceutical Sciences. 2026;220:107463. https:\/\/doi.org\/10.1016\/j.ejps.2026.107463.","journal-title":"European Journal of Pharmaceutical Sciences"},{"key":"4689_CR165","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2025.107622","volume":"114","author":"H Ho\u0159avov\u00e1","year":"2025","unstructured":"Ho\u0159avov\u00e1 H, Pe\u0161t\u00e1lov\u00e1 A, Pavlokov\u00e1 S, K\u00e1nsk\u00e1 J, L\u00edzal F, Gajdziok J. Spray-dried solid inhalable N-acetylcysteine microparticles: preparation and mucolytic activity testing. Journal of Drug Delivery Science and Technology. 2025;114:107622. https:\/\/doi.org\/10.1016\/j.jddst.2025.107622.","journal-title":"Journal of Drug Delivery Science and Technology"},{"key":"4689_CR166","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.actbio.2025.07.068","volume":"204","author":"Y Wang","year":"2025","unstructured":"Wang Y, Xuan W, Mao C, Liu Y. Inhalable nucleic acid therapeutics for chronic pulmonary disease: progress, challenges, and prospects. Acta Biomater. 2025;204:187\u2013204. https:\/\/doi.org\/10.1016\/j.actbio.2025.07.068.","journal-title":"Acta Biomater"},{"key":"4689_CR167","doi-asserted-by":"publisher","first-page":"114081","DOI":"10.1016\/j.addr.2021.114081","volume":"181","author":"KA Afonin","year":"2022","unstructured":"Afonin KA, Dobrovolskaia MA, Ke W, Grodzinski P, Bathe M. Critical review of nucleic acid nanotechnology to identify gaps and inform a strategy for accelerated clinical translation. Adv Drug Delivery Rev. 2022;181:114081. https:\/\/doi.org\/10.1016\/j.addr.2021.114081.","journal-title":"Adv Drug Delivery Rev"},{"key":"4689_CR168","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2025.139532","volume":"295","author":"P Vosoughi","year":"2025","unstructured":"Vosoughi P, Naghib SM, Kangarshahi BM, Mozafari MR. A review of RNA nanoparticles for drug\/gene\/protein delivery in advanced therapies: current state and future prospects. Int J Biol Macromol. 2025;295:139532. https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.139532.","journal-title":"Int J Biol Macromol"},{"issue":"8","key":"4689_CR169","doi-asserted-by":"publisher","first-page":"9221","DOI":"10.1021\/acsnano.0c04753","volume":"14","author":"KA Afonin","year":"2020","unstructured":"Afonin KA, Dobrovolskaia MA, Church G, Bathe M. Opportunities, barriers, and a strategy for overcoming translational challenges to therapeutic nucleic acid nanotechnology. ACS Nano. 2020;14(8):9221\u20137. https:\/\/doi.org\/10.1021\/acsnano.0c04753.","journal-title":"ACS Nano"},{"issue":"10","key":"4689_CR170","doi-asserted-by":"publisher","first-page":"3828","DOI":"10.1039\/d1cs00617g","volume":"51","author":"Y Xiao","year":"2022","unstructured":"Xiao Y, Tang Z, Huang X, et al. Emerging mRNA technologies: delivery strategies and biomedical applications. Chem Soc Rev. 2022;51(10):3828\u201345. https:\/\/doi.org\/10.1039\/d1cs00617g.","journal-title":"Chem Soc Rev"},{"issue":"709","key":"4689_CR171","doi-asserted-by":"publisher","first-page":"eabq0603","DOI":"10.1126\/scitranslmed.abq0603","volume":"15","author":"A Suberi","year":"2023","unstructured":"Suberi A, Grun MK, Mao T, et al. Polymer nanoparticles deliver mRNA to the lung for mucosal vaccination. Sci Transl Med. 2023;15(709):eabq0603. https:\/\/doi.org\/10.1126\/scitranslmed.abq0603.","journal-title":"Sci Transl Med"},{"key":"4689_CR172","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/bs.ai.2024.12.001","volume":"165","author":"AK Singh","year":"2025","unstructured":"Singh AK, Goel K, Dhanawat M. Plasmid DNA and mRNA delivery: approaches and challenges. Adv Immunol. 2025;165:63\u201387. https:\/\/doi.org\/10.1016\/bs.ai.2024.12.001.","journal-title":"Adv Immunol"},{"key":"4689_CR173","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201805116","author":"A P","year":"2019","unstructured":"P A, K J, B S, et al. Inhaled nanoformulated mRNA polyplexes for protein production in lung epithelium. Advanced Materials. 2019. https:\/\/doi.org\/10.1002\/adma.201805116.","journal-title":"Advanced Materials"},{"key":"4689_CR174","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2024.122753","author":"K Ew","year":"2025","unstructured":"Ew K, Sy T, N S, Gr C, Jj G. Ligand-free biodegradable poly(beta-amino ester) nanoparticles for targeted systemic delivery of mRNA to the lungs. Biomaterials. 2025. https:\/\/doi.org\/10.1016\/j.biomaterials.2024.122753.","journal-title":"Biomaterials"},{"issue":"3","key":"4689_CR175","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41565-018-0358-x","volume":"14","author":"S Guan","year":"2019","unstructured":"Guan S, Munder A, Hedtfeld S, et al. Self-assembled peptide\u2013poloxamine nanoparticles enable in vitro and in vivo genome restoration for cystic fibrosis. Nat Nanotechnol. 2019;14(3):287\u201397. https:\/\/doi.org\/10.1038\/s41565-018-0358-x.","journal-title":"Nat Nanotechnol"},{"issue":"12","key":"4689_CR176","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.3390\/cells12121555","volume":"12","author":"G Wang","year":"2023","unstructured":"Wang G. Genome editing for cystic fibrosis. Cells. 2023;12(12):1555. https:\/\/doi.org\/10.3390\/cells12121555.","journal-title":"Cells"},{"key":"4689_CR177","doi-asserted-by":"publisher","first-page":"124054","DOI":"10.1016\/j.ijbiomac.2023.124054","volume":"238","author":"S Bhatia","year":"2023","unstructured":"Bhatia S, Pooja N, Yadav SK. CRISPR-cas for genome editing: classification, mechanism, designing and applications. Int J Biol Macromol. 2023;238:124054. https:\/\/doi.org\/10.1016\/j.ijbiomac.2023.124054.","journal-title":"Int J Biol Macromol"},{"issue":"39","key":"4689_CR178","doi-asserted-by":"publisher","first-page":"14348","DOI":"10.1021\/acs.nanolett.5c03548","volume":"25","author":"RA Joseph","year":"2025","unstructured":"Joseph RA, Haley RM, Padilla MS, Ricciardi AS, Yamagata HM, Mitchell MJ. Cas9 Protein Outperforms mRNA in Lipid Nanoparticle-Mediated CFTR Repair. Nano Lett. 2025;25(39):14348\u201355. https:\/\/doi.org\/10.1021\/acs.nanolett.5c03548.","journal-title":"Nano Lett"},{"key":"4689_CR179","doi-asserted-by":"publisher","first-page":"114053","DOI":"10.1016\/j.jconrel.2025.114053","volume":"385","author":"B Tafech","year":"2025","unstructured":"Tafech B, Carlaw T, Sadhnani G, et al. Lung tissue-optimized gene editing in human cystic fibrosis models following topical application of lipid nanoparticles. J Control Release. 2025;385:114053. https:\/\/doi.org\/10.1016\/j.jconrel.2025.114053.","journal-title":"J Control Release"},{"issue":"6701","key":"4689_CR180","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1126\/science.adk9428","volume":"384","author":"Y Sun","year":"2024","unstructured":"Sun Y, Chatterjee S, Lian X, et al. In vivo editing of lung stem cells for durable gene correction in mice. Science. 2024;384(6701):1196\u2013202. https:\/\/doi.org\/10.1126\/science.adk9428.","journal-title":"Science"},{"issue":"5","key":"4689_CR181","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1089\/nat.2022.0004","volume":"32","author":"SF Dowdy","year":"2022","unstructured":"Dowdy SF, Setten RL, Cui XS, Jadhav SG. Delivery of RNA therapeutics: the great endosomal escape! Nucleic Acid Ther. 2022;32(5):361\u20138. https:\/\/doi.org\/10.1089\/nat.2022.0004.","journal-title":"Nucleic Acid Ther"},{"issue":"1","key":"4689_CR182","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1021\/acs.accounts.1c00544","volume":"55","author":"Y Eygeris","year":"2022","unstructured":"Eygeris Y, Gupta M, Kim J, Sahay G. Chemistry of lipid nanoparticles for RNA delivery. Acc Chem Res. 2022;55(1):2\u201312. https:\/\/doi.org\/10.1021\/acs.accounts.1c00544.","journal-title":"Acc Chem Res"},{"issue":"5","key":"4689_CR183","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1002\/jbm.a.35296","volume":"103","author":"PR Wardwell","year":"2015","unstructured":"Wardwell PR, Bader RA. Immunomodulation of cystic fibrosis epithelial cells via NF-\u03baB decoy oligonucleotide-coated polysaccharide nanoparticles. J Biomed Mater Res A. 2015;103(5):1622\u201331. https:\/\/doi.org\/10.1002\/jbm.a.35296.","journal-title":"J Biomed Mater Res A"},{"issue":"6","key":"4689_CR184","doi-asserted-by":"publisher","first-page":"7565","DOI":"10.1021\/acsami.1c14975","volume":"14","author":"G Conte","year":"2022","unstructured":"Conte G, Costabile G, Baldassi D, et al. Hybrid Lipid\/Polymer Nanoparticles to Tackle the Cystic Fibrosis Mucus Barrier in siRNA Delivery to the Lungs: Does PEGylation Make the Difference? ACS Appl Mater Interfaces. 2022;14(6):7565\u201378. https:\/\/doi.org\/10.1021\/acsami.1c14975.","journal-title":"ACS Appl Mater Interfaces"},{"key":"4689_CR185","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jconrel.2022.09.021","volume":"351","author":"CM Zimmermann","year":"2022","unstructured":"Zimmermann CM, Baldassi D, Chan K, et al. Spray drying siRNA-lipid nanoparticles for dry powder pulmonary delivery. J Control Release. 2022;351:137\u201350. https:\/\/doi.org\/10.1016\/j.jconrel.2022.09.021.","journal-title":"J Control Release"},{"issue":"10","key":"4689_CR186","doi-asserted-by":"publisher","first-page":"3060","DOI":"10.1016\/j.apsb.2021.04.023","volume":"11","author":"Q Qiao","year":"2021","unstructured":"Qiao Q, Liu X, Yang T, et al. Nanomedicine for acute respiratory distress syndrome: the latest application, targeting strategy, and rational design. Acta Pharm Sin B. 2021;11(10):3060\u201391. https:\/\/doi.org\/10.1016\/j.apsb.2021.04.023.","journal-title":"Acta Pharm Sin B"},{"issue":"28","key":"4689_CR187","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.2174\/1381612828666220727144223","volume":"28","author":"V Krishnaswami","year":"2022","unstructured":"Krishnaswami V, Kandasamy R. Current drug targeting using siRNA-based nano therapeutics for pulmonary diseases. Curr Pharm Des. 2022;28(28):2279\u201382. https:\/\/doi.org\/10.2174\/1381612828666220727144223.","journal-title":"Curr Pharm Des"},{"issue":"1","key":"4689_CR188","doi-asserted-by":"publisher","first-page":"e2400510","DOI":"10.1002\/adhm.202400510","volume":"14","author":"R Maeshima","year":"2025","unstructured":"Maeshima R, Tagalakis AD, Gyftaki-Venieri D, et al. Low Molecular Weight Alginate Oligosaccharides as Alternatives to PEG for Enhancement of the Diffusion of Cationic Nanoparticles Through Cystic Fibrosis Mucus. Adv Healthc Mater. 2025;14(1):e2400510. https:\/\/doi.org\/10.1002\/adhm.202400510.","journal-title":"Adv Healthc Mater"},{"key":"4689_CR189","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jconrel.2014.11.022","volume":"198","author":"J Deacon","year":"2015","unstructured":"Deacon J, Abdelghany SM, Quinn DJ, et al. Antimicrobial efficacy of tobramycin polymeric nanoparticles for Pseudomonas aeruginosa infections in cystic fibrosis: Formulation, characterisation and functionalisation with dornase alfa (DNase). J Controlled Release. 2015;198:55\u201361. https:\/\/doi.org\/10.1016\/j.jconrel.2014.11.022.","journal-title":"J Controlled Release"},{"issue":"12","key":"4689_CR190","doi-asserted-by":"publisher","first-page":"100939","DOI":"10.1016\/j.jpha.2024.01.007","volume":"14","author":"T Tchatchiashvili","year":"2024","unstructured":"Tchatchiashvili T, Duering H, Mueller-Boetticher L, et al. PEG-PLGA nanoparticles deposited in Pseudomonas aeruginosa and Burkholderia cenocepacia. J Pharm Anal. 2024;14(12):100939. https:\/\/doi.org\/10.1016\/j.jpha.2024.01.007.","journal-title":"J Pharm Anal"},{"key":"4689_CR191","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.jconrel.2024.08.029","volume":"374","author":"G Costabile","year":"2024","unstructured":"Costabile G, Baldassi D, M\u00fcller C, et al. Antibiotic-loaded nanoparticles for the treatment of intracellular methicillin-resistant Staphylococcus Aureus infections: In vitro and in vivo efficacy of a novel antibiotic. J Controlled Release. 2024;374:454\u201365. https:\/\/doi.org\/10.1016\/j.jconrel.2024.08.029.","journal-title":"J Controlled Release"},{"issue":"4","key":"4689_CR192","doi-asserted-by":"publisher","first-page":"5695","DOI":"10.1021\/acsami.4c14991","volume":"17","author":"Y Chen","year":"2025","unstructured":"Chen Y, Xu M, Pan J, et al. Moxifloxacin-Loaded Polymeric Nanoparticles for Overcoming Multidrug Resistance in Chronic Pulmonary Infections Caused by Pseudomonas aeruginosa. ACS Appl Mater Interfaces. 2025;17(4):5695\u2013709. https:\/\/doi.org\/10.1021\/acsami.4c14991.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"2","key":"4689_CR193","doi-asserted-by":"publisher","first-page":"162","DOI":"10.3390\/pharmaceutics18020162","volume":"18","author":"PK Baral","year":"2026","unstructured":"Baral PK, Dummer J, Pletzer D, Das SC. Inhaled antibiotic and biologic formulations targeting pseudomonas aeruginosa. Pharmaceutics. 2026;18(2):162. https:\/\/doi.org\/10.3390\/pharmaceutics18020162.","journal-title":"Pharmaceutics"},{"issue":"4","key":"4689_CR194","doi-asserted-by":"publisher","first-page":"CD004197","DOI":"10.1002\/14651858.CD004197.pub5","volume":"4","author":"SC Langton Hewer","year":"2017","unstructured":"Langton Hewer SC, Smyth AR. Antibiotic strategies for eradicating pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev. 2017;4(4):CD004197. https:\/\/doi.org\/10.1002\/14651858.CD004197.pub5.","journal-title":"Cochrane Database Syst Rev"},{"issue":"24","key":"4689_CR195","doi-asserted-by":"publisher","first-page":"e2100531","DOI":"10.1002\/smll.202100531","volume":"17","author":"CR Thorn","year":"2021","unstructured":"Thorn CR, Carvalho-Wodarz C, de Horstmann S, Lehr JC, Prestidge CM, Thomas CA. Tobramycin liquid crystal nanoparticles eradicate cystic fibrosis-related pseudomonas aeruginosa biofilms. Small. 2021;17(24):e2100531. https:\/\/doi.org\/10.1002\/smll.202100531.","journal-title":"Small"},{"issue":"1","key":"4689_CR196","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1021\/acsami.9b19644","volume":"12","author":"F Wan","year":"2020","unstructured":"Wan F, Bohr SSR, K\u0142odzi\u0144ska SN, et al. Ultrasmall TPGS-PLGA hybrid nanoparticles for site-specific delivery of antibiotics into pseudomonas aeruginosa biofilms in lungs. ACS Appl Mater Interfaces. 2020;12(1):380\u20139. https:\/\/doi.org\/10.1021\/acsami.9b19644.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"5","key":"4689_CR197","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/s41579-020-00477-5","volume":"19","author":"E Rossi","year":"2021","unstructured":"Rossi E, La Rosa R, Bartell JA, et al. Pseudomonas aeruginosa adaptation and evolution in patients with cystic fibrosis. Nat Rev Microbiol. 2021;19(5):331\u201342. https:\/\/doi.org\/10.1038\/s41579-020-00477-5.","journal-title":"Nat Rev Microbiol"},{"issue":"13","key":"4689_CR198","doi-asserted-by":"publisher","first-page":"19276","DOI":"10.1021\/acsami.4c20874","volume":"17","author":"LJP Rooney","year":"2025","unstructured":"Rooney LJP, Marshall A, Tunney MM, Tabaei SR. Phenylboronic acid-modified polyethyleneimine: a glycan-targeting anti-biofilm polymer for inhibiting bacterial adhesion to mucin and enhancing antibiotic efficacy. ACS Appl Mater Interfaces. 2025;17(13):19276\u201385. https:\/\/doi.org\/10.1021\/acsami.4c20874.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"46","key":"4689_CR199","doi-asserted-by":"publisher","DOI":"10.1002\/adfm.202402868","volume":"34","author":"K Ivanova","year":"2024","unstructured":"Ivanova K, Ramon E, Wnorowska U, et al. Integrated Biofilm Dispersion and Virulence Responsiveness for Targeted Treatment of Pseudomonas aeruginosa Infection in Lungs. Adv Funct Mater. 2024;34(46):2402868. https:\/\/doi.org\/10.1002\/adfm.202402868.","journal-title":"Adv Funct Mater"},{"issue":"4","key":"4689_CR200","doi-asserted-by":"publisher","first-page":"5695","DOI":"10.1021\/acsami.4c14991","volume":"17","author":"Y Chen","year":"2025","unstructured":"Chen Y, Xu M, Pan J, et al. Moxifloxacin-loaded polymeric nanoparticles for overcoming multidrug resistance in chronic pulmonary infections caused by pseudomonas aeruginosa. ACS Appl Mater Interfaces. 2025;17(4):5695\u2013709. https:\/\/doi.org\/10.1021\/acsami.4c14991.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"9","key":"4689_CR201","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1002\/adhm.201500974","volume":"5","author":"DN Amato","year":"2016","unstructured":"Amato DN, Amato DV, Mavrodi OV, et al. Destruction of opportunistic pathogens via polymer nanoparticle-mediated release of plant-based antimicrobial payloads. Adv Healthc Mater. 2016;5(9):1094\u2013103. https:\/\/doi.org\/10.1002\/adhm.201500974.","journal-title":"Adv Healthc Mater"},{"issue":"2","key":"4689_CR202","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s11095-025-03985-2","volume":"43","author":"Y Varela Soler","year":"2026","unstructured":"Varela Soler Y, Padilla-L\u00f3pez AS, Rao S, et al. Aerosol delivery of polyelectrolyte surfactant-antimicrobial nanoparticles to the lungs. Pharm Res. 2026;43(2):421\u201333. https:\/\/doi.org\/10.1007\/s11095-025-03985-2.","journal-title":"Pharm Res"},{"key":"4689_CR203","doi-asserted-by":"publisher","DOI":"10.1016\/j.nantod.2025.102889","volume":"66","author":"C Zhao","year":"2026","unstructured":"Zhao C, Xiao A, Chen C, Mu W, Li WY, Chang L. Nanotechnology for diagnosis and therapy of idiopathic pulmonary fibrosis: Recent advances and future perspectives. Nano Today. 2026;66:102889. https:\/\/doi.org\/10.1016\/j.nantod.2025.102889.","journal-title":"Nano Today"},{"issue":"1","key":"4689_CR204","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12951-025-03800-5","volume":"24","author":"Y Quan","year":"2025","unstructured":"Quan Y, Yang H, Li W, Li L. mRNA vaccines: immunogenicity and quality characteristics. J Nanobiotechnol. 2025;24(1):6. https:\/\/doi.org\/10.1186\/s12951-025-03800-5.","journal-title":"J Nanobiotechnol"},{"issue":"1","key":"4689_CR205","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12951-025-04019-0","volume":"24","author":"S Xu","year":"2026","unstructured":"Xu S, Li M, Wang T, et al. Lung-targeted RNA delivery systems: strategies and therapeutic applications. J Nanobiotechnol. 2026;24(1):142. https:\/\/doi.org\/10.1186\/s12951-025-04019-0.","journal-title":"J Nanobiotechnol"},{"issue":"1","key":"4689_CR206","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1186\/s12951-022-01605-4","volume":"20","author":"S Waheed","year":"2022","unstructured":"Waheed S, Li Z, Zhang F, Chiarini A, Armato U, Wu J. Engineering nano-drug biointerface to overcome biological barriers toward precision drug delivery. J Nanobiotechnol. 2022;20(1):395. https:\/\/doi.org\/10.1186\/s12951-022-01605-4.","journal-title":"J Nanobiotechnol"},{"issue":"1","key":"4689_CR207","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1186\/s12951-024-02758-0","volume":"22","author":"Y Zhuo","year":"2024","unstructured":"Zhuo Y, Zeng H, Su C, Lv Q, Cheng T, Lei L. Tailoring biomaterials for vaccine delivery. J Nanobiotechnol. 2024;22(1):480. https:\/\/doi.org\/10.1186\/s12951-024-02758-0.","journal-title":"J Nanobiotechnol"},{"issue":"1","key":"4689_CR208","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1186\/s12951-025-03762-8","volume":"23","author":"NS Shrikrishna","year":"2025","unstructured":"Shrikrishna NS, Gandhi S. Nanopore-based sensing for biomarker detection: from fundamental principles to translational diagnostics. J Nanobiotechnol. 2025;23(1):663. https:\/\/doi.org\/10.1186\/s12951-025-03762-8.","journal-title":"J Nanobiotechnol"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-026-04689-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-04689-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-04689-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:11:41Z","timestamp":1787584301000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12951-026-04689-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":208,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4689"],"URL":"https:\/\/doi.org\/10.1186\/s12951-026-04689-4","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]},"assertion":[{"value":"21 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"806"}}